The US Food and Drug Administration has proposed new conflict-of-interest waiver guidelines that would publicly identify the companies or institutions at issue when an advisory panel member has a financial conflict. The proposal is aimed at boosting transparency behind the agency’s decision ...
Please Login to read the full article.
